A Phase 3 interventional study of GSK1278863 and Iron in Anaemia, sponsored by GlaxoSmithKline. Completed at 17 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-12-03.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 22nd largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 3, and was the 15th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 27th largest by enrollment, is one of 6 that started in 2016, is one of 10 in phase 3, and was the 20th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 24-week, Phase 3, open-label, non-comparative, multicentre study aims to evaluate the efficacy and safety of GSK1278863 in Japanese hemodialysis (HD) patients with renal anemia not using erythropoiesis-stimulating agents (ESAs). The primary objective is to evaluate the initial response to GSK1278863 measured by hemoglobin (Hgb) levels in HD patients not using ESAs enrolled in this study. The study is designed to evaluate the appropriateness of the starting dose of GSK1278863 and of the GSK1278863 dose adjustment regimen to achieve or maintain the target Hgb levels. This study will consist of a 4-week screening period, a 24-week treatment period (4-week fixed-dose period and a 20-week dose adjustment period), and a 2- to 4-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotropin [hCG] test for females of [FRP] only), not breastfeeding, and at least one of the following conditions applies:
Females of reproductive potential who agree to follow one of the options listed in the "GlaxoSmithKline (GSK) Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential" from 28 days before the first dose of study treatment until completion of the follow-up visit.
Exclusion Criteria:
CKD related criteria
Cardiovascular disease-related criteria
Other disease-related criteria
Liver disease (if any of the following occurs):
Concomitant medications and other study treatment-related criteria
Note:
Patients on anti-hyperphosphatemia medication containing iron (e.g., ferric citrate hydrate) for at least 12 weeks before screening may be enrolled if the medication is continued during the screening and from Day 1 to Week 4.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
Drug: GSK1278863 · Drug: Iron
GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
Change From Baseline in Hgb at Week 4
Blood samples were collected from participants for measurement of Hgb values. The Baseline value was the latest pre-dose assessment. Change from Baseline at Week 4 was calculated by subtracting Baseline value from the post-dose visit value. The analysis was performed on All Treated Subjects Population which comprised of all participants who received at least one dose of GSK1278863.
Time frame: Baseline and Week 4
Number of Participants by Hgb Change From Baseline Category at Week 4
Blood samples were collected from participants for measurement of Hgb values. The Baseline value was the latest pre-dose assessment. Change from Baseline at Week 4 was calculated by subtracting Baseline value from the post-dose visit value. The change in Hgb at Week 4 was classified into different categories (i.e., \<=-2.0, \>-2.0 to -1.0, \>-1.0 to 0, \>0 to 1.0, \>1.0 to 2.0, and \>2 g/dL), and the number of participants in each category were summarized.
Time frame: Baseline and Week 4
Hgb Values at the Indicated Time Points
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer.
Time frame: Up to Week 24
Change From Baseline in Hgb at the Indicated Time Points
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The Baseline value was the latest pre-dose assessment. Change from Baseline at indicated time-points was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to Week 24
Number of Participants Who Had Hgb Level Within the Target Range (10.0-12.0 g/dL)
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants with Hgb withinthe target range (10.0 to 12.0 g/dL) at each assessment visit was summarized.
Time frame: Up to Week 24
Time to Reach the Lower Target Hgb Level (10.0 g/dL)
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. Participants who could not reach lower target were regarded as censored. The time (in days) to reach the lower target Hgb level (10.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method.
Time frame: Up to Week 24
Number of Participants Who Had Hgb Level of Less Than 7.5 g/dL
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb level of less than 7.5 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.
Time frame: Up to Week 24
Number of Participants Who Had Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb increase of more than 2.0 g/dL over any 4 weeks were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.
Time frame: Up to Week 24
Number of Participants Who Had Hgb Level of More Than 13.0 g/dL
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb level of more than 13.0 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.
Time frame: Up to Week 24
Number of Episodes of Achieving Hgb Level of More Than 13.0 g/dL
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of episodes in participants who had Hgb level of more than 13.0 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.
Time frame: Up to Week 24
Area Under the Concentration-time Curve (AUC) From Time Zero to 4 Hours (AUC [0-4]) of GSK1278863
Blood samples were collected to evaluate AUC (0-4) at 1, 2, 3 and 4 hours post dose at Weeks 12 and 24. Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Population consisted of all participants who received GSK1278863 with the PK samples collected and analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indiates data was not available. Geometric coefficient of variation could not be calculated when number of participant was equal to 1.
Time frame: 1, 2, 3 and 4 hours post dose at Weeks 12 and 24
Maximum Observed Concentration (Cmax) of GSK1278863
Blood samples were collected to evaluate Cmax at 1, 2, 3 and 4 hours post dose at Weeks 12 and 24. PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indiates data was not available. Geometric coefficient of variation could not be calculated when number of participant was equal to 1.
Time frame: 1, 2, 3 and 4 hours post dose at Weeks 12 and 24
Monthly Average Dose of Intravenous (IV) Iron During the Treatment Period
Records of on-therapy iron medication were used to calculate average quarterly IV iron dose. Quarter 1 = (Randomization Date - Treatment Start Date at Week 12 - 1 \[day\]). Quarter 2 = (Treatment Start Date at Week 12 - Study Treatment Stop Date). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Up to Week 24
Number of Participants Who Used Iron During the Treatment Period
The number of participants who used iron (both IV and oral iron) during the treatment period were summarized.
Time frame: Up to Week 24
Change From Baseline in Ferritin
Blood samples were collected from participants for measurement of serum ferritin at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to Week 24
Percent Change From Baseline in TSAT
Blood samples were collected from participants for measurement of TSAT at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1).
Time frame: Baseline and up to Week 24
Percent Change From Baseline in Hepcidin
Blood samples were collected from participants for measurement of hepcidin at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). If a laboratory value had a non-detectable level reported in the database, where the numeric value was missing, the value was not included in a summary. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and up to Week 24
Change From Baseline in Serum Iron
Blood samples were collected from participants for measurement of serum iron at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to Week 24
Change From Baseline in Total Iron Binding Capacity (TIBC)
Blood samples were collected from participants for measurement of TIBC at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to Week 24
Dose Level of GSK1278863 at Indicated Time Points
Dose adjustment algorithm was used which was based on Hgb values at scheduled visits. Hgb values measured at unscheduled visits were not included. Mean dose during Week 12 to 24 is the average of dose at Weeks 12, 16, and 20.
Time frame: Up to Week 24
Number of Participants With Frequency of Dose Adjustments
Dose adjustment algorithm was used which was based on Hgb values at scheduled visits. Hgb values measured at unscheduled visits were not included. For dose adjustments frequency, the number of participants were provided by the number of dose adjustments (i.e. zero, one, two, three, four, and five or more).
Time frame: Up to Week 24
Duration of Treatment Interruption Due to Hgb >13 g/dL
Hgb values were used for making decision of treatment interruption. On-therapy Hgb values observed in both scheduled and unscheduled visits were counted. Participants who have no treatment interruption due to Hgb \>13.0 g/dL are not included
Time frame: Up to Week 24
This was a 24-week, Phase 3, open-label, non-comparative, multicenter study to evaluate the efficacy and safety of GSK1278863 in Japanese hemodialysis participants with renal anemia not using Erythropoiesis Stimulating Agents. The study was conducted at 18 centers in Japan from 08-Aug-2016 to 17-Oct-2017.
| Milestone | All Participants |
|---|---|
| Started | 28 |
| Completed | 28 |
| Not completed | 0 |
Blood samples were collected from participants for measurement of Hgb values. The Baseline value was the latest pre-dose assessment. Change from Baseline at Week 4 was calculated by subtracting Baseline value from the post-dose visit value. The analysis was performed on All Treated Subjects Population which comprised of all participants who received at least one dose of GSK1278863.
| G/dL | All Participants |
|---|---|
| Change From Baseline in Hgb at Week 4 | 0.79 (0.53 to 1.05) |
Blood samples were collected from participants for measurement of Hgb values. The Baseline value was the latest pre-dose assessment. Change from Baseline at Week 4 was calculated by subtracting Baseline value from the post-dose visit value. The change in Hgb at Week 4 was classified into different categories (i.e., \<=-2.0, \>-2.0 to -1.0, \>-1.0 to 0, \>0 to 1.0, \>1.0 to 2.0, and \>2 g/dL), and the number of participants in each category were summarized.
| Participants | All Participants |
|---|---|
| <= -2.0 | 0 |
| > -2.0 to -1.0 | 0 |
| > -1.0 to 0 | 4 |
| > 0 to 1.0 | 13 |
| > 1.0 to 2.0 | 11 |
| > 2.0 | 0 |
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer.
| G/dL | All Participants |
|---|---|
| Day 1 | 9.10 ± 0.696 |
| Week 4 | 9.90 ± 0.907 |
| Week 8 | 10.76 ± 0.957 |
| Week 12 | 11.09 ± 1.117 |
| Week 16 | 11.38 ± 1.286 |
| Week 20 | 11.34 ± 1.169 |
| Week 24 | 11.12 ± 1.210 |
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The Baseline value was the latest pre-dose assessment. Change from Baseline at indicated time-points was calculated by subtracting Baseline value from the post-dose visit value.
| G/dL | All Participants |
|---|---|
| Week 4 | 0.79 ± 0.673 |
| Week 8 | 1.66 ± 0.773 |
| Week 12 | 1.98 ± 0.984 |
| Week 16 | 2.28 ± 1.248 |
| Week 20 | 2.24 ± 1.174 |
| Week 24 | 2.01 ± 1.121 |
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants with Hgb withinthe target range (10.0 to 12.0 g/dL) at each assessment visit was summarized.
| Participants | All Participants |
|---|---|
| Day 1, within range | 3 |
| Week 4, within range | 13 |
| Week 8, within range | 20 |
| Week 12, within range | 18 |
| Week 16, within range | 17 |
| Week 20, within range | 20 |
| Week 24, within range | 23 |
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. Participants who could not reach lower target were regarded as censored. The time (in days) to reach the lower target Hgb level (10.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method.
| Days | All Participants |
|---|---|
| Time to Reach the Lower Target Hgb Level (10.0 g/dL) | 57.0 (29.0 to 57.0) |
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb level of less than 7.5 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.
| Participants | All Participants |
|---|---|
| Number of Participants Who Had Hgb Level of Less Than 7.5 g/dL | 0 |
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb increase of more than 2.0 g/dL over any 4 weeks were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.
| Participants | All Participants |
|---|---|
| Number of Participants Who Had Hgb Increase of More Than 2 g/dL Over Any 4 Weeks | 1 |
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb level of more than 13.0 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.
| Participants | All Participants |
|---|---|
| Number of Participants Who Had Hgb Level of More Than 13.0 g/dL | 3 |
Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of episodes in participants who had Hgb level of more than 13.0 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.
| Episodes | All Participants |
|---|---|
| Number of Episodes of Achieving Hgb Level of More Than 13.0 g/dL | 7 |
Blood samples were collected to evaluate AUC (0-4) at 1, 2, 3 and 4 hours post dose at Weeks 12 and 24. Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Population consisted of all participants who received GSK1278863 with the PK samples collected and analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indiates data was not available. Geometric coefficient of variation could not be calculated when number of participant was equal to 1.
| Hour*nanogram per milliliter (h*ng/mL) | GSK1278863 1 mg | GSK1278863 2 mg | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 12 mg | GSK1278863 18 mg |
|---|---|---|---|---|---|---|---|
| AUC (0-4), Week 12, n=0,4,14,8,1,0,0 | — | 25.7228 ± 289.9 | 95.1319 ± 111.9 | 200.6036 ± 62.9 | 233.3933 ± NA | — | — |
| AUC (0-4), Week 24, n=1,8,8,5,2,1,1 | 43.3100 ± NA | 33.8941 ± 230.9 | 86.3702 ± 58.9 | 133.3020 ± 50.9 | 437.0983 ± 18.7 | 749.4583 ± NA | 126.2883 ± NA |
| AUC (0-4), All, n=1,12,22,13,3,1,1 | 43.3100 ± NA | 30.9164 ± 225.3 | 91.8474 ± 91.1 | 171.4229 ± 60.8 | 354.6083 ± 40.0 | 749.4583 ± NA | 126.2883 ± NA |
Blood samples were collected to evaluate Cmax at 1, 2, 3 and 4 hours post dose at Weeks 12 and 24. PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indiates data was not available. Geometric coefficient of variation could not be calculated when number of participant was equal to 1.
| ng/mL | GSK1278863 1 mg | GSK1278863 2 mg | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 12 mg | GSK1278863 18 mg |
|---|---|---|---|---|---|---|---|
| Cmax, Week 12, n=0,4,14,8,1,0,0 | — | 13.9578 ± 340.6 | 57.6572 ± 81.2 | 122.9883 ± 56.9 | 179.0000 ± NA | — | — |
| Cmax, Week 24, n=1,8,8,5,2,1,1 | 27.5000 ± NA | 18.3448 ± 202.3 | 44.8853 ± 49.8 | 100.2261 ± 41.3 | 202.9384 ± 3.5 | 311.0000 ± NA | 93.4000 ± NA |
| Cmax, All, n=1,12,22,13,3,1,1 | 27.5000 ± NA | 16.7474 ± 217.4 | 52.6391 ± 70.4 | 113.6784 ± 50.4 | 194.6229 ± 7.7 | 311.0000 ± NA | 93.4000 ± NA |
Records of on-therapy iron medication were used to calculate average quarterly IV iron dose. Quarter 1 = (Randomization Date - Treatment Start Date at Week 12 - 1 \[day\]). Quarter 2 = (Treatment Start Date at Week 12 - Study Treatment Stop Date). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Mg | All Participants |
|---|---|
| Quarter 1; n= 3 | 231.61 ± 99.916 |
| Quarter 2; n= 4 | 217.19 ± 86.529 |
The number of participants who used iron (both IV and oral iron) during the treatment period were summarized.
| Participants | All Participants |
|---|---|
| Oral iron | 9 |
| Intravenous iron | 4 |
| Any iron medication | 12 |
Blood samples were collected from participants for measurement of serum ferritin at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Microgram per liter (µg/L) | All Participants |
|---|---|
| Week 4 | -80.11 ± 51.826 |
| Week 12 | -126.29 ± 120.382 |
| Week 24 | -107.03 ± 143.048 |
Blood samples were collected from participants for measurement of TSAT at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1).
| Percentage of transferrin | All Participants |
|---|---|
| Week 4 | -23.06 (-32.43 to -12.38) |
| Week 12 | -15.31 (-33.79 to 8.32) |
| Week 24 | -10.07 (-25.49 to 8.55) |
Blood samples were collected from participants for measurement of hepcidin at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). If a laboratory value had a non-detectable level reported in the database, where the numeric value was missing, the value was not included in a summary. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
| Percentage of hepcidin | All Participants |
|---|---|
| Week 4, n=26 | -64.78 (-71.34 to -56.71) |
| Week 12, n=22 | -61.74 (-74.51 to -42.57) |
| Week 24, n=21 | -55.67 (-72.52 to -28.47) |
Blood samples were collected from participants for measurement of serum iron at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Micromoles per liter (µmol/L) | All Participants |
|---|---|
| Week 4 | -0.8123 ± 4.92624 |
| Week 12 | 2.0916 ± 10.74722 |
| Week 24 | 1.4584 ± 7.72121 |
Blood samples were collected from participants for measurement of TIBC at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| umol/L | All Participants |
|---|---|
| Week 4 | 8.5904 ± 4.93732 |
| Week 12 | 10.8611 ± 6.32355 |
| Week 24 | 9.3388 ± 9.92131 |
Dose adjustment algorithm was used which was based on Hgb values at scheduled visits. Hgb values measured at unscheduled visits were not included. Mean dose during Week 12 to 24 is the average of dose at Weeks 12, 16, and 20.
| mg | All Participants |
|---|---|
| Day 1 | 4.0 (4 to 4) |
| Week 4 | 4.0 (2 to 6) |
| Week 8 | 4.0 (2 to 8) |
| Week 12 | 4.0 (0 to 8) |
| Week 16 | 4.0 (0 to 12) |
| Week 20 | 4.0 (0 to 18) |
| Week 12 to 24 | 4.00 (0.0 to 12.7) |
Dose adjustment algorithm was used which was based on Hgb values at scheduled visits. Hgb values measured at unscheduled visits were not included. For dose adjustments frequency, the number of participants were provided by the number of dose adjustments (i.e. zero, one, two, three, four, and five or more).
| Participants | All Participants |
|---|---|
| Any dose adjustments | 21 |
| Number of dose adjustments=0 | 7 |
| Number of dose adjustments=1 | 9 |
| Number of dose adjustments=2 | 7 |
| Number of dose adjustments=3 | 4 |
| Number of dose adjustments=4 | 1 |
| Number of dose adjustments=5 or more | 0 |
Hgb values were used for making decision of treatment interruption. On-therapy Hgb values observed in both scheduled and unscheduled visits were counted. Participants who have no treatment interruption due to Hgb \>13.0 g/dL are not included
| Days | All Participants |
|---|---|
| Duration of Treatment Interruption Due to Hgb >13 g/dL | 84 (28 to 84) |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of study treatment (Day 1) until Week 24.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 0/28 (0%) | 3/28 (10.7%) | 12/28 (42.9%) |
| Event | All Participants |
|---|---|
| Shunt occlusionInjury, poisoning and procedural complications | 2/28 |
| Device dislocationProduct Issues | 1/28 |
| Event | All Participants |
|---|---|
| NasopharyngitisInfections and infestations | 9/28 |
| Infected dermal cystInfections and infestations | 2/28 |
| Shunt stenosisInjury, poisoning and procedural complications | 2/28 |
All Treated Subjects
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 62.5 ± 10.16 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 3 |
| Male | 25 |
| Race/Ethnicity, Customized(Count of Participants) | All Participants |
|---|---|
| Asian - Japanese Heritage | 28 |
| Dialysis Status(Participants) | All Participants |
|---|---|
| Newly started dialysis | 11 |
| Maintenance dialysis | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2016 to primary completion in May 2017, 9 months.
Results were first posted in Jul 2018, 1 year 1 month after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 9 months is below that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863